PHARMACOKINETICS OF F105, A HUMAN MONOCLONAL-ANTIBODY, IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1

F105 is a human monoclonal antibody that binds to the CD4 binding site of human immunodeficiency virus type 1 gp120 and neutralizes clinical and laboratory isolates of the human immunodeficiency virus, This pha se I study investigated the disposition of the antibody in humans. F10 5 was administered over a 60-minute period at two dose levels, 100 and 500 mg/m(2). Blood samples were obtained for up to 56 days, The clear ance of the antibody was 0.33 ml/min with a corresponding half-life of approximately 13 days, Peak concentrations achieved at the higher dos e level were 216.19 +/- 9.62 mu g/ml. The disposition of the drug mas linear for the doses studied, Simulations were performed to design fut ure studies aimed at investigating the efficacy of the antibody, This study concluded that F105 can be administered as a bolus dose every 21 days.